Clone of Breaking the Cycle: Approaches to Long-term Weight Loss and Obesity Care- Evaluation | the Endocrine Society Center for Learning

The Endocrine Society strives to offer high quality CME programs that are educationally rigorous, balanced and free from commercial bias. Please help us maintain this important standard by providing the requested information in the activity assessment below:

On average, how many patients with adult growth hormone disorder (aGHD) do you see in 1 week? *

1 to 5

5 to 10

10-15

>15

Information provided in this presentation will promote the practice of evidence-based medicine *

	5 Agree	4	3	2	1 Disagree
Program Introduction and Preactivity Assessment	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 5 Agree	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 4	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 3	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 2	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 1 Disagree	Mark E Molitch, MD
How Does aGHD Present and How Should the Diagnosis Be Confirmed?	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 5 Agree	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 4	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 3	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 2	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 1 Disagree	Julie Silverstein, MD
What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 5 Agree	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 4	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 3	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 2	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 1 Disagree	Julie Silverstein, MD
What Techniques Can Provide Solutions to the Challenges of Treating aGHD?	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 5 Agree	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 4	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 3	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 2	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 1 Disagree	David R Clemmons, MD
What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 5 Agree	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 4	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 3	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 2	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 1 Disagree	David R Clemmons, MD

Overall Activity Evaluation *

	5 Agree	4	3	2	1 Disagree
The educational content was useful and relevant to my practice	The educational content was useful and relevant to my practice - 5 Agree	The educational content was useful and relevant to my practice - 4	The educational content was useful and relevant to my practice - 3	The educational content was useful and relevant to my practice - 2	The educational content was useful and relevant to my practice - 1 Disagree
The educational format was effective	The educational format was effective - 5 Agree	The educational format was effective - 4	The educational format was effective - 3	The educational format was effective - 2	The educational format was effective - 1 Disagree

Activity Evaluation *

	Yes	No
The information provided in this presentation enhanced my knowledge and will enable me to provide better care for my patients with GHD.	The information provided in this presentation enhanced my knowledge and will enable me to provide better care for my patients with GHD. - Yes	The information provided in this presentation enhanced my knowledge and will enable me to provide better care for my patients with GHD. - No

What 1 question remains unanswered after having participated in this activity?

Please cite 1 new piece of information that you learned from this activity.

What endocrinology topics would you like to see offered in future continuing education activities?

Please evaluate how well the following learning objectives were met. Upon completion of this activity, participants should be able to: *

	5 Met	4	3	2	1 Not Met
Identify aGHD based on presenting disease features and results of appropriate diagnostic tests	Identify aGHD based on presenting disease features and results of appropriate diagnostic tests - 5 Met	Identify aGHD based on presenting disease features and results of appropriate diagnostic tests - 4	Identify aGHD based on presenting disease features and results of appropriate diagnostic tests - 3	Identify aGHD based on presenting disease features and results of appropriate diagnostic tests - 2	Identify aGHD based on presenting disease features and results of appropriate diagnostic tests - 1 Not Met
Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics	Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics - 5 Met	Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics - 4	Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics - 3	Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics - 2	Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients’ clinical and personal characteristics - 1 Not Met
Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring	Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring - 5 Met	Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring - 4	Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring - 3	Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring - 2	Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring - 1 Not Met
Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood	Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood - 5 Met	Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood - 4	Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood - 3	Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood - 2	Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood - 1 Not Met

Mark E. Molitch, MD Evaluation *

	Yes	No
The content was clinically/scientifically sound & evidence-based	The content was clinically/scientifically sound & evidence-based - Yes	The content was clinically/scientifically sound & evidence-based - No
The content was objective and free of commercial bias	The content was objective and free of commercial bias - Yes	The content was objective and free of commercial bias - No
I would recommend this speaker/ presentation to a colleague	I would recommend this speaker/ presentation to a colleague - Yes	I would recommend this speaker/ presentation to a colleague - No

If you answered “no” to the previous statement, please explain why

Julie M. Silverstein, Md Evaluation *

	Yes	No
The content was clinically/scientifically sound & evidence-based	The content was clinically/scientifically sound & evidence-based - Yes	The content was clinically/scientifically sound & evidence-based - No
The content was objective and free of commercial bias	The content was objective and free of commercial bias - Yes	The content was objective and free of commercial bias - No
I would recommend this speaker/ presentation to a colleague	I would recommend this speaker/ presentation to a colleague - Yes	I would recommend this speaker/ presentation to a colleague - No

If you answered “no” to the previous statement, please explain why

David R. Clemmons, MD Evaluation *

	Yes	No
The content was clinically/scientifically sound & evidence-based	The content was clinically/scientifically sound & evidence-based - Yes	The content was clinically/scientifically sound & evidence-based - No
The content was objective and free of commercial bias	The content was objective and free of commercial bias - Yes	The content was objective and free of commercial bias - No
I would recommend this speaker/ presentation to a colleague	I would recommend this speaker/ presentation to a colleague - Yes	I would recommend this speaker/ presentation to a colleague - No

If you answered “no” to the previous statement, please explain why

Commitment to Change *

	Yes	No
After attending this activity, I am committed to making changes in the way I treat my patients with GHD.	After attending this activity, I am committed to making changes in the way I treat my patients with GHD. - Yes	After attending this activity, I am committed to making changes in the way I treat my patients with GHD. - No

If yes, please describe 1 thing you plan to change in your practice as a result of this activity.

Additional Comments

Leave this field blank

	5 Agree	4	3	2	1 Disagree
Program Introduction and Preactivity Assessment	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 5 Agree	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 4	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 3	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 2	Program Introduction and Preactivity Assessment\| Mark E Molitch, MD - 1 Disagree	Mark E Molitch, MD
How Does aGHD Present and How Should the Diagnosis Be Confirmed?	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 5 Agree	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 4	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 3	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 2	How Does aGHD Present and How Should the Diagnosis Be Confirmed?\| Julie Silverstein, MD - 1 Disagree	Julie Silverstein, MD
What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 5 Agree	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 4	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 3	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 2	What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?\| Julie Silverstein, MD - 1 Disagree	Julie Silverstein, MD
What Techniques Can Provide Solutions to the Challenges of Treating aGHD?	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 5 Agree	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 4	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 3	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 2	What Techniques Can Provide Solutions to the Challenges of Treating aGHD?\| David R Clemmons, MD - 1 Disagree	David R Clemmons, MD
What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 5 Agree	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 4	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 3	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 2	What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition to Adulthood?\| David R Clemmons, MD - 1 Disagree	David R Clemmons, MD

the Endocrine Society Center for Learning

Hormone Science to Health

ENDO Online Ancillary Symposium - Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder

Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder- Webcast Evaluation

Presentation: Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder

Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder- Webcast Evaluation

Credit

Certificate

Course navigation

You are here

ENDO Online Ancillary Symposium - Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder

Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder- Webcast Evaluation

Presentation: Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder

Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder- Webcast Evaluation

Credit

Certificate

Course navigation